First Trust Switzerland AlphaDEX Fund (FSZ)

What does this fund actually track?

FSZ focuses specifically on Swiss-listed companies in the small and mid-cap range, selected using the AlphaDEX methodology. Rather than holding the entire Swiss market or even all mid-caps in Switzerland, the fund applies a systematic screen to identify companies that combine valuation discipline with fundamental quality. The screening process looks for firms that appear undervalued relative to their cash generation and growth prospects, while also exhibiting balance-sheet strength and operational efficiency. Switzerland, as a developed market with stable regulatory frameworks and a concentration of multinational industrial and pharmaceutical firms, offers a specific subset of businesses that appeal to investors with geographic conviction or those hedging against currency exposure.

Why would an investor care about Swiss companies specifically?

Switzerland is home to a disproportionately large number of global pharmaceutical and chemical companies, precision manufacturing firms, and financial services businesses. Companies like Novartis, Roche, Nestlé, and ABB have Swiss heritage and listing, and so do dozens of smaller specialists in areas like industrial automation, diagnostics, and specialty materials. Switzerland also benefits from low corporate taxes, a stable legal system, and a culture of corporate precision that appeals to both European and global investors. An investor interested in European exposure might allocate to a broad Europe fund; an investor with conviction on Switzerland specifically might use FSZ to gain that focused access.

The Swiss market also cycles differently from the broader European or global markets. Swiss firms are often highly dependent on global economic growth rather than local Swiss demand, which means the market responds more to worldwide business cycles than to Swiss economic conditions. During periods when investors shy away from periphery-European assets but maintain appetite for Swiss quality, FSZ may outperform broader European funds.

How does AlphaDEX screening work in a Swiss context?

The AlphaDEX methodology, developed by Wisdom Tree and licensed by First Trust, combines momentum and value signals. In a Swiss mid-cap context, this typically means identifying companies that are trading at low multiples of cash flow or earnings (the value component) while also showing positive momentum in their business metrics or stock price (the momentum component). The goal is to avoid value traps — companies that are cheap but getting cheaper because fundamentals are deteriorating — by requiring that some forward-looking signal confirms that the valuation discount is genuinely exploitable.

In practice, Swiss small and mid-caps captured by this screen tend to be companies with stable, mature cash generation, reasonable balance sheets, and perhaps recently improving profitability after a period of weakness. The pharmaceutical and chemical sectors, with their long product cycles and predictable cash flows, often appear prominently. So do industrial and machinery companies that serve global markets and have just recovered from a cyclical trough.

What are the costs and trading characteristics?

FSZ is a straightforward ETF with an expense ratio typically in the 0.60% to 0.75% range. The fund holds between 80 and 150 securities, depending on how many Swiss mid-caps pass the AlphaDEX screen at any given time. Because the fund is focused on a single developed but small country, liquidity can be tighter than for broader funds — trading volume is lower, and wide bid-ask spreads are not uncommon. Investors should use limit orders and avoid trying to buy or sell large positions in a single block, as the fund’s assets and daily volume may not support moving massive sums without market impact.

How does this fund perform across economic cycles?

Swiss mid-cap stocks are tied to global growth cycles more tightly than to Swiss economic conditions. When the world economy is robust, Swiss exporters and multinational companies benefit; when global growth slows, the market compresses. The AlphaDEX screen, by tilting toward companies at valuation inflection points, may outperform in the early stages of recoveries, when despised sectors are rebounding but have not yet re-rated to fair value. In late-cycle expansions, when all stocks are priced for perfection, the value component of the screen may lag.

Switzerland’s role as a safe-haven asset during geopolitical stress or financial market turbulence can also drive Swiss franc appreciation, which creates a tailwind for the fund when measured in US dollars. Conversely, during periods of American strength and dollar appreciation, the currency drag can weigh on returns.

Who should consider this fund, and how to research it?

FSZ appeals to investors with specific conviction on Switzerland as a market, those seeking European exposure through a politically and economically stable country, or those wanting to add Swiss franc currency exposure to a portfolio. It is not a core-portfolio holding for most investors, but rather a satellite or conviction bet.

Research should begin with the fund’s prospectus and holdings list, to understand which specific Swiss companies are currently held and whether they align with your thesis. Review the fund’s performance relative to the broad Swiss market index and to other European small-cap funds to assess whether the AlphaDEX screen is adding value. Examine the portfolio’s sector concentration — is it heavily pharmaceuticals, or is it more diversified? Pay attention to currency dynamics, because a significant portion of returns in Swiss-focused funds will come from franc movements relative to the dollar. And finally, assess the fund’s liquidity and trading spread before committing capital, as tight liquidity can make exits costly.

What risks should investors understand?

The primary risk is concentration in a single small country. While Switzerland is politically stable and economically sophisticated, a fund holding 100+ Swiss stocks still has less diversification than a global fund holding 500+. Sector concentration is another concern — if the fund is heavily weighted toward pharmaceuticals and one major firm faces a drug-approval setback, the entire portfolio may be meaningfully affected. Currency risk is both a feature and a risk: a strengthening franc is a tailwind if you are benchmarked in dollars, but a weakening franc becomes a drag. Finally, the AlphaDEX screen, while rational, is backward-looking. A company that appears cheap and has momentum today may face deteriorating fundamentals tomorrow if global growth slows or competitive pressures intensify.